- SD 0006
-
- $53.00 / 5mg
-
2024-11-19
- CAS:271576-80-8
- Min. Order:
- Purity: 98.32%
- Supply Ability: 10g
|
| | 3-[N-(2-Hydroxyacetyl)-4-piperidyl]-4-(4-pyrimidinyl)-5-(4-chlorophenyl)pyrazole Basic information |
| | 3-[N-(2-Hydroxyacetyl)-4-piperidyl]-4-(4-pyrimidinyl)-5-(4-chlorophenyl)pyrazole Chemical Properties |
| Boiling point | 652.6±55.0 °C(Predicted) | | density | 1.367 | | storage temp. | 2-8°C | | solubility | DMSO : 50 mg/mL (125.67 mM; Need ultrasonic) | | form | Powder | | pka | 9.39±0.50(Predicted) | | color | White to off-white |
| | 3-[N-(2-Hydroxyacetyl)-4-piperidyl]-4-(4-pyrimidinyl)-5-(4-chlorophenyl)pyrazole Usage And Synthesis |
| Definition | ChEBI: SD-06 is a member of the class of pyrazoles that is 1H-pyrazole in which the hydrogens at positions 3, 4, and 5 are replaced by N-(hydroxyacetyl)piperidin-4-yl, pyrimidin-4-yl and p-chlorophenyl groups, respectively. It is a member of pyrazoles, a member of pyrimidines, a N-acylpiperidine, a member of monochlorobenzenes and a primary alcohol. | | Biological Activity | SD 0006 (SD-06) is an orally potent, selective, ATP-competitive, and potent diarylpyrazole inhibitor of p38α MAPK with IC50 of 110 nM. | | in vitro | SD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate. | | in vivo | SD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy.It(3.75, 7.5 and 15 mg/kg; po; bid) is highly effective in attenuating SCW-induced inflammation as shown by the dose-dependent inhibition of paw swelling. | | target | |
| | 3-[N-(2-Hydroxyacetyl)-4-piperidyl]-4-(4-pyrimidinyl)-5-(4-chlorophenyl)pyrazole Preparation Products And Raw materials |
|